Previous 10 | Next 10 |
Patience is a virtue, or so says an old proverb. That sentiment certainly applies to the stock market. The longer one holds shares of great companies, the greater the potential for compounding to work its magic. That's why the buy and hold strategy works. However, it can be tough to find qu...
Exact Sciences Applauds Proposed CMS Change to Colorectal Cancer Screening Policy PR Newswire MADISON, Wis. , July 8, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, applauds the ...
Exact Sciences schedules second quarter 2022 earnings call PR Newswire MADISON, Wis. , July 8, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to...
Yesterday I made a call that the Market bottomed on 6/16. Barchart's Trend Spotter has moved from Sell to Hold on ARKK. 35 of the Fund's 36 holdings have a positive return over the last 5 days. The Chart of the Day belongs to the controversial and highly followed ETF...
Ultima Genomics and Exact Sciences enter long-term supply agreement aimed at improving patient access to genomic testing by driving down sequencing costs PR Newswire NEWARK, Calif. and MADISON, Wis. , June 21, 2022 /PRNewswire/ -- Ultima Genomics, Inc...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Many of these Cathie Wood stocks have faced significant challenges in the first half of 2022. Wood’s innovation-focused exchange-traded funds (ETFs) were all the rage on Wall Street until the recent market downturn....
Founded in 2006 by Morty Schaja and Mitch Rubin, RiverPark manages research-driven, focused strategies in equities, fixed income and venture capital. Over this year’s first three months, the RiverPark Large Growth Fund (the “Fund”) lost 19.6%. Rather than foll...
Exact Sciences Showcases Breadth of Early Detection and Treatment Guidance Portfolio with Multiple Data Presentations at ASCO 2022 PR Newswire MADISON, Wis. , May 27, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer di...
The current tight macro environment is conducive to consolidation in Biotech. Exact Sciences needs to turn cash flow positive to avoid liquidity problems. M&A might be a solution to scale and reduce cash burn, but it doesn't come without problems. For further details see...
Liquid biopsies provide hope for quicker and more accurate early-stage cancer detection across a wider range of cancer types with a simple blood test. Using current standard of care, only about 25% of cancers are detected via screening. The remaining 75% are detected when the patient ...
News, Short Squeeze, Breakout and More Instantly...
Exact Sciences Corporation Company Name:
EXAS Stock Symbol:
NASDAQ Market:
Exact Sciences Corporation Website:
2024-07-11 08:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-08 08:30:00 ET To say that Exact Sciences (NASDAQ: EXAS) hasn't performed well on the stock market this year would be an understatement. Shares of the cancer-focused biotech are down by 41%. However, the healthcare company still has some fans on Wall Street. Cathie Wood ...
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after the close of the U.S. financial markets on July 31, 2024. Following the release, company management w...